Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial

Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial | ReachRx